“保胆”理念正误

胆囊切除术是公认的胆囊良性疾病的治愈手段，国内外学术界对于手术适应证和手术时机已有明确共识。近年来，“保胆手术”治疗胆囊良性疾病颇受热议，一些医生将“保护胆囊”的学术观点等同于“保留胆囊”的手术技术，这种误解可能导致病人出现差异性的预后。因此，临床医师应明晰“保护胆囊”理念与“保胆手术”的差别，对胆囊良性疾病的诊疗原则有正确的理解和应用。     

Minimally Invasive Treatments for Benign Prostatic Hyperplasia: Systematic Review and Network Meta-Analysis

PurposeTo review and to compare indirectly the outcomes of minimally invasive therapies for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.Materials and MethodsA literature search via Medline and Cochrane Central databases was completed for randomized control studies published between January 2000 to April 2020 for the following therapies: Rezum, Urolift, Aquablation, and prostatic artery embolization (PAE). Data on the following variables were included: International prostate symptom score (IPSS), maximum urinary flow rate, quality of life, and postvoid residual (PVR). Standard mean differences between treatments were compared through a meta-analysis using transurethral resection of the prostate (TURP) to assess differences in treatment effect.ResultsThere was no significant difference in outcomes between therapies for IPSS at the 3, 6, and 12-month follow ups. Although outcomes for Rezum were only available out to 3 months, there were no consistently significant differences in outcomes when comparing Aquablation versus PAE versus Rezum. TURP PVR was significantly better than Urolift at 3, 6, and 12 months. No significant differences in minor or major adverse events were noted.ConclusionAlthough significant differences in outcomes were limited, Aquablation and PAE were the most durable at 12 months. PAE has been well studied on multiple randomized control trials with minimal adverse events while Aquablation has limited high quality data and has been associated with bleeding-related complications.     

Tadalafil for the treatment of benign prostatic hyperplasia

Introduction: In men, lower urinary tract symptoms (LUTS) are primarily attributed to benign prostatic hyperplasia (BPH). Therapeutic options are targeted to relax prostate smooth muscle and/or reduce prostate enlargement.

Areas covered: This article reviews the major preclinical and clinical data on PDE5 inhibitors with a specific focus on tadalafil. It includes details of the role of the nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) – PDE5 pathway in the LUT organs (bladder and prostate) in addition to the available data on tadalafil in patients with LUTS secondary to BPH with or without erectile dysfunction (ED).

Expert opinion: Preclinical and clinical data have clearly demonstrated that PDE5 inhibitors induce bladder and prostate relaxation, which contributes to the improvement seen in storage symptoms in both animal models of bladder and prostate hypercontractility. Tadalafil is effective both as a monotherapy and add-on therapy in patients with LUTS secondary to BPH. Furthermore, as LUTS-BPH and ED are urological disorders that commonly coexist in aging men, tadalafil is more advantageous than α1-adrenoceptors and should be used as the first option. Tadalafil is a safe and tolerable therapy and unlike α1- adrenoceptors and 5-alpha reductase inhibitors, which can cause sexual dysfunctions, tadalafil improves sexual function.     

尿动力学检查在前列腺增生症术前评估中的临床意义

目的探讨前列腺增生症(BPH)手术治疗前尿动力学检查的必要性。方法对166例拟行手术治疗的BPH患者的尿动力学检查结果进行分析。结果在166例患者中,125例(75.3%)证实存在膀胱出口梗阻(BOO ),25例(15.1%)为可疑BOO(BOO±),16例(9.6%)无BOO(BOO-),3组之间在最大尿流率(Qmax)、残余尿量(PVRV)、逼尿肌/外括约肌协同失调(DSD)上差异无统计意义,BOO( )组的逼尿肌不稳定(DI)、低顺应性膀胱的发生率明显高于其他两组,逼尿肌收缩力减弱(DUA)的发生率明显低于其他两组。结论尿动力学检查对诊断BPH、选择治疗方法和预测疗效有重要意义,手术治疗前应常规检查。     

Successful choledochojejunostomy for choledochal stricture with preservation of the collateral parabiliary venous system following iatrogenic portal occlusion

We surgically treated a patient with biliary stricture and portal vein occlusion, after operation for gastric cancer with lymphadenectomy along the hepatoduodenal ligament, that had led to choledochal stone formation and a dilatated parabiliary venous system. A 57-year-old man without hepatic dysfunction exhibited hepatic duct dilatation with choledochal stone on ultrasonography and percutaneous transhepatic cholangiography, respectively. Pharmacoportography revealed occlusion of the portal vein and dilatation of the parabiliary venous system. Of various preoperative imaging studies used, enhanced computed tomography was most useful for delineating the surgical anatomy of the hepatoduodenal ligament. Complete preservation of the dilatated vessels, which functioned as the main portal collateral pathway, resulted in a successful choledocho-jejunostomy, with an uneventful postoperative course.     

良性前列腺增生中医证型与尿动力学参数相关性研究

目的:探讨良性前列腺增生(BPH)中医证型与尿动力学参数的相关性。方法:152例BPH患者,中医辨证分为肾阴不足、肾阳虚弱、瘀阻水道、脾气虚弱、肺热气郁、湿热下注、痰浊郁结七型,均进行尿动力学检查。结果:152例BPH患者中,肾阳虚弱型71例(46.71%),瘀阻水道型40例(26.31%),肾阴不足型14例(9.21%)。膀胱出口梗阻为III～VI度肾阳虚弱型有58例,瘀阻水道型有38例,其中严重梗阻(V～VI)26例。膀胱逼尿肌收缩功能极弱中(n=12),肾阳虚弱型4例,占33.33%(4/12),瘀阻水道型7例,占58.33%(7/12);膀胱逼尿肌收缩功能弱者中(n=48),肾阳虚弱型为27例,占56.25%(27/48),瘀阻水道型17例,占35.42%(17/48)。结论:BPH中医各辨证分型与膀胱出口梗阻和膀胱逼尿肌收缩力有一定的相关性,从而为中医证型的量化和客观化提供相应的证据。     

腮腺良性和恶性多形性腺瘤的超声研究

目的研究腮腺良性和恶性多形性腺瘤的超声特点,为临床医师诊治提供有效依据。方法选取腮腺良性多形性腺瘤患者79例和恶性多形性腺瘤患者15例,对其肿块的大小、硬度、内部回声、彩色多普勒血流显像(CDFI)特点结合病理学诊断进行对照研究。结果恶性多形性腺瘤的声像图特点与良性多形性腺瘤相似,但其肿瘤相对较大,质地更硬,内部回声分布更紊乱。不同性质的肿瘤的大小和质地有显著性差异,(P<0.01)。结论多形性腺瘤的超声诊断主要依据二维图像之特点。当多形性腺瘤大于3.0 cm,硬度较硬,内部回声分布不均多提示恶性。     

输卵管卵巢脓肿与卵巢良性肿瘤的CT鉴别诊断

目的:分析输卵管卵巢脓肿的CT特征,探讨CT对输卵管卵巢脓肿与卵巢附件良性肿瘤的鉴别诊断价值。材料和方法:回顾性分析13例输卵管卵巢脓肿和11例卵巢良性肿瘤的CT表现。结果:绝经前患者输卵管卵巢脓肿12例(12/13例),良性肿瘤组4例(4/11例)。脓肿13例(13/13例)、良性肿瘤9例(9/11例),CT表现为附件区囊实性肿块,脓肿和良性肿瘤边缘轮廓模糊不清分别为11例(11/13例)和4例(4/11例),两组显示囊壁增厚和边缘层状增强分别为10例(10/13例)和2例(2/11例)。脓肿的子宫骶骨韧带增厚和骶前直肠周围脂肪模糊分别为10/13例和9/11例,而良性肿瘤组无1例发生。结论:附件脓肿壁增厚和层状增强,子宫骶骨韧带增厚及骶前直肠周围脂肪模糊有助于鉴别输卵管卵巢脓肿和卵巢良性肿瘤。     

腹腔镜结合术中内窥镜治疗结直肠良性病变13例分析

目的 探讨腹腔镜手术结合术中内窥镜治疗结直肠良性病变的方法和临床意义.方法 回顾性分析2004年6月至2006年12月13例结直肠良性病变以腹腔镜结合术中内窥镜治疗的患者的临床资料.结果 结肠多发性息肉1例,息肉3枚,直径1.5 cm～2.5 cm,乙状结肠、降结肠和直肠上段单发息肉或腺瘤11例,病变直径1.5 cm～3.0 cm,降结肠憩室并出血1例,直径1 cm,全部患者均在腹腔镜下结合术中内窥镜定位,经腹壁小切口找到定位处肠管切开后完整切除病变或缝扎憩室.无术后并发症.结论 腹腔镜结合术中内窥镜治疗结直肠良性病变定位准确、创伤小、安全有效,适合结直肠大部分位置良性疾病的治疗.